ciglitazone has been researched along with u 0126 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, F; Harrison, LE; Kim, E; Wang, CC | 1 |
Chae, JJ; Chang, HK; Kim, DS; Kim, M; Lee, KH; Lee, MW; Myong, JP; Park, TC | 1 |
2 other study(ies) available for ciglitazone and u 0126
Article | Year |
---|---|
Ciglitazone-induced p27 gene transcriptional activity is mediated through Sp1 and is negatively regulated by the MAPK signaling pathway.
Topics: Binding Sites; Butadienes; Cyclin-Dependent Kinase Inhibitor p27; Flavonoids; Gene Expression Regulation; HT29 Cells; Humans; Luciferases; MAP Kinase Signaling System; Nitriles; Phosphorylation; Plicamycin; Promoter Regions, Genetic; Sp1 Transcription Factor; Thiazolidinediones; Time Factors; Transcription, Genetic; Transfection | 2005 |
Inhibition of ERK activity enhances the cytotoxic effect of peroxisome proliferator-activated receptor γ (PPARγ) agonists in HeLa cells.
Topics: Antineoplastic Agents; Apoptosis; Butadienes; Caspase 3; Cell Survival; Cervix Uteri; Chromans; Drug Synergism; Enzyme Inhibitors; Female; HeLa Cells; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitriles; PPAR gamma; Thiazolidinediones; Troglitazone; Uterine Cervical Neoplasms | 2017 |